Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20^th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021. The Company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta’s proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-301264794.html

SOURCE Viracta